Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Vifor Pharma
Vifor Pharma
Activities:
Manufacturing
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Finance
Vifor Pharma to propose Åsa Riisberg for board of directors
Riisberg holds a MSc in Financial Economics and Business Administration from Stockholm School of Economics
Ingredients
Vifor Pharma enters Chinese joint venture with Fresenius Kabi
Joint venture will bring IV Iron to China to replace the wasteful blood transfusions that are the current prevailing treatment for iron deficiency anaemia
Finance
Vifor Pharma enters commercial diabetes collaboration in the US
The Swiss pharma company will work with US-based Janssen to jointly commercialise INVOKANA (canagliflozin) in the US to address complications of type 2 diabetes
Drug Delivery
PIVOTAL trial confirms long-term safety and efficacy of IV iron dosing
The long-term safety and efficacy of intravenous iron dosing has been confirmed allowing higher Ferritin concentration and transferrin saturation in patients undergoing haemodialysis
Recruitment
Vifor pharma announces management changes
Media
Vifor Pharma proposes Jacques Theurillat as board member
Pharmaceutical
Kissei to market Avacopan in Japan for Vifor Pharma
Vifor Fresenius Medical Care Renal Pharma has granted Japanese pharmaceutical company, Kissei, exclusive rights to develop and commercialise Avacopan in Japan
Subscribe now